Smad1 Protein

A receptor-regulated smad protein that undergoes PHOSPHORYLATION by BONE MORPHOGENETIC PROTEIN RECEPTORS. It regulates BONE MORPHOGENETIC PROTEIN signaling and plays an essential role in EMBRYONIC DEVELOPMENT.

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Gao, Y Q: 1 article (01/2016)
2.	Liu, M: 1 article (01/2016)
3.	Zhang, H: 1 article (01/2016)
4.	Dong, Jianning: 1 article (03/2014)
5.	Gong, Jianfeng: 1 article (03/2014)
6.	Gu, Lili: 1 article (03/2014)
7.	Li, Jieshou: 1 article (03/2014)
8.	Li, Ning: 1 article (03/2014)
9.	Li, Yi: 1 article (03/2014)
10.	Liu, Jianhui: 1 article (03/2014)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 01/01/2016 - "The aim of this study is to detect the expression profiles of SMAD1 protein in lung cancer tissues and normal tissues to investigate its effect on the incidence of lung cancer. " 01/01/2016 - "The expression profiles of SMAD1 protein in 60 cases of lung cancer tissues (lung cancer group), 25 cases of normal alveolus tissues (alveolus control group) and 29 cases of normal bronchial tissues (bronchial control group) were detected by adopting immunohistochemical analyses, and their relationships with clinicopathologic data were analyzed. " 01/01/2016 - "Expression profiles of SMAD1 protein in lung cancer tissues and normal tissues and its effect on lung cancer incidence." 01/01/2016 - "The expression of SMAD1 protein in the lung cancer group and the lung squamous cell carcinoma group was significantly lower than that in the alveolus control group and the bronchial control group (P < 0.01). " 01/01/2016 - "The expression of SMAD1 protein in the lung adenocarcinoma group was significantly lower than that in the alveolus control group and the bronchial control group (P < 0.01); The expression SMAD1 protein showed a significant correlation with lung cancer differentiation and lymphatic metastasis (P < 0.05), but not with genders, ages, tumor sizes and histological types of lung cancer patients (P>0.05)."
2.	Weight Loss (Weight Reduction) 03/28/2014 - "IL-10- / - mice treated with CD52 mAb showed a reduction in the percentage of CD4+ and CD4+CD45+ T cells in blood and weight loss typically associated with colonic inflammation, serum levels of EPO, the expression of liver hepcidin mRNA and total Smad1 protein, while they showed an increase in Hb concentrations, haematocrit, levels of serum Fe, transferrin saturation and splenic Fe stores. "
3.	Neoplasms (Cancer) 01/01/2016 - "The expression of SMAD1 protein in the lung adenocarcinoma group was significantly lower than that in the alveolus control group and the bronchial control group (P < 0.01); The expression SMAD1 protein showed a significant correlation with lung cancer differentiation and lymphatic metastasis (P < 0.05), but not with genders, ages, tumor sizes and histological types of lung cancer patients (P>0.05)."
4.	Lymphatic Metastasis 01/01/2016 - "The expression of SMAD1 protein in the lung adenocarcinoma group was significantly lower than that in the alveolus control group and the bronchial control group (P < 0.01); The expression SMAD1 protein showed a significant correlation with lung cancer differentiation and lymphatic metastasis (P < 0.05), but not with genders, ages, tumor sizes and histological types of lung cancer patients (P>0.05)."
5.	Inflammation (Inflammations) 03/28/2014 - "IL-10- / - mice treated with CD52 mAb showed a reduction in the percentage of CD4+ and CD4+CD45+ T cells in blood and weight loss typically associated with colonic inflammation, serum levels of EPO, the expression of liver hepcidin mRNA and total Smad1 protein, while they showed an increase in Hb concentrations, haematocrit, levels of serum Fe, transferrin saturation and splenic Fe stores. "

Related Drugs and Biologics

1.	Hepcidins
2.	Transferrin (beta 2 Transferrin)
3.	Messenger RNA (mRNA)